PAP-1

Catalog No.E0378 Batch:E037801

Technical Data

Formula	C₂₁H₁₈O₅
Molecular Weight	350.37	CAS No.	870653-45-5
Solubility (25°C)*	In vitro	DMSO	70 mg/mL (199.78 mM)
		Ethanol	25 mg/mL (71.35 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

PAP-1 (5-(4-phenoxybutoxy)psoralen), a Kv1.3 antagonist with an EC50 of 2 nM, inhibits the proliferation of human T cells and suppresses delayed type hypersensitivity in rats.

Targets

Kv1.3 ^[1]

2 nM(EC50)

In vitro

PAP-1 (2-100 nM; 30 minutes) suppresses the proliferation of CCR7-TEM cells with IC⁵⁰ of 10 nM.^[1]

In vivo

PAP-1 (0.3-3 mg/kg; i.p.; three times daily for 48 hours) prevents delayed type hypersensitivity (DTH) in lewis rats.^[1]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines CCR7-TEM cells Concentrations 2-100 nM Incubation Time 30 min Method CCR7- T cells are then seeded at 5 X 104 per well together with 5 X 104 autologous irradiated peripheral blood mononuclear cells in RPMI culture medium into round-bottomed, 96-well plates. PAP-1 is added at different concentrations, and the cells are stimulated with 25 ng/ml soluble anti-CD3 Ab 30 min later. Cells are harvested onto glassfiber filters, and radioactivity is measured in a ß-scintillation counter.

Cell Assay:^{^[1]}

Cell lines
CCR7-TEM cells
Concentrations
2-100 nM
Incubation Time
30 min
Method
CCR7- T cells are then seeded at 5 X 104 per well together with 5 X 104 autologous irradiated peripheral blood mononuclear cells in RPMI culture medium into round-bottomed, 96-well plates. PAP-1 is added at different concentrations, and the cells are stimulated with 25 ng/ml soluble anti-CD3 Ab 30 min later. Cells are harvested onto glassfiber filters, and radioactivity is measured in a ß-scintillation counter.

References

[1] Schmitz A, et al. Mol Pharmacol. 2005 Nov;68(5):1254-70.

Selleck's PAP-1 has been cited by 1 publication

Bergapten attenuates microglia-mediated neuroinflammation and ischemic brain injury by targeting Kv1.3 and Carbonyl reductase 1 [ Eur J Pharmacol, 2022, 933:175242]	PubMed: 36058290

Bergapten attenuates microglia-mediated neuroinflammation and ischemic brain injury by targeting Kv1.3 and Carbonyl reductase 1 [ Eur J Pharmacol, 2022, 933:175242]

PubMed: 36058290

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.